Stock Code: 301033 Stock Abbreviation: Medprin Listing Venue: Shenzhen Stock Exchange
Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
Report (Draft) Summary on Issuance of Shares and Payment of Cash to Purchase Assets and Raise Supporting Funds and Related Party Transactions
(Review Draft)
| Item | Name |
|---|---|
| Counterparties to Asset Purchase | Guangzhou Zexin Medical Technology Co., Ltd. |
| Guangzhou Yichuangxiang Investment Partnership (Limited Partnership) | |
| Guangzhou Huangpu Pilot Medical Venture Capital Fund Partnership (Limited Partnership) | |
| Guangdong Jieke Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) | |
| Hu Ganwei | |
| Guangzhou Fuheng Investment Co., Ltd. | |
| Yuan Ziyang | |
| Guangzhou Industrial Investment Biomedical and Health Special Mother Fund Partnership (Limited Partnership) | |
| Guangzhou Industrial Investment Productivity Venture Capital Partnership (Limited Partnership) | |
| Guangzhou Youjiu Equity Investment Center (Limited Partnership) | |
| Subscribers to Supporting Funds | Guangzhou Yijian Medical Investment Co., Ltd. |
Independent Financial Advisor
Huatai United Securities Co., Ltd.
Signing Date: June 2026
Declaration
The terms or abbreviations used in this section have the same meanings as those defined in the "Definitions" section of this report summary.
I. Statement of the Listed Company
The Company and all its directors and senior management guarantee that the information disclosed by the Company is timely and fair, and that the contents of this report summary are true, accurate, and complete, without false records, misleading statements, or major omissions. They guarantee the truthfulness and reasonableness of the data cited in this report summary and assume corresponding legal liability for the truthfulness, accuracy, and completeness of the information provided.
If the information disclosed or provided in this transaction is suspected of containing false records, misleading statements, or major omissions, and is subject to case investigation by judicial authorities or the China Securities Regulatory Commission (CSRC), the parties involved shall not transfer their equity interests in the listed company until the investigation concludes. They shall submit a written application for suspension of transfer and their stock account to the Company's Board of Directors within two trading days of receiving the investigation notice, and the Board shall apply for a lock-up on their behalf to the stock exchange and the securities registration and clearing institution. If the application is not submitted within two trading days, the Board is authorized to verify and directly report the identity and account information to the stock exchange and the securities registration and clearing institution to apply for a lock-up. If the Board fails to report such information, the stock exchange and the securities registration and clearing institution are authorized to directly lock the relevant shares. If the investigation reveals illegal or non-compliant conduct, the parties commit to voluntarily using the locked shares for investor compensation arrangements.
Any decisions or opinions made by the CSRC or the Shenzhen Stock Exchange regarding this transaction do not represent a substantive judgment or guarantee of the value of the Company's shares or investor returns.
In accordance with the Securities Law and other relevant laws and regulations, after the completion of this transaction, the Company is solely responsible for changes in its operations and earnings, and investors are solely responsible for investment risks arising from such changes. When evaluating this transaction, investors should carefully consider the risk factors disclosed in this report summary in addition to the content of this report summary and other simultaneously disclosed documents. Investors with any questions should consult their stock brokers, lawyers, accountants, or other professional advisors.